To note, a recent study in murine Triple-Negative Breast Cancer (TNBC) and colorectal cancer cells demonstrated that combined treatment of ERβ agonist and PD-1 antibody, reduced Myeloid-Derived Suppressor Cells (MDSC) tumor infiltration and enhanced its response to ICB therapy 44. Here, ESR2 is linked to triple-negative breast carcinoma.